VAL201 in concluding stages of Phase I/II trial

VALIRX PLC

("ValiRx" or the "Company")

VAL201 ENTERS THE CONCLUDING STAGES OF ITS PHASE l/ll CLINICAL TRIAL

London, UK., 17 October 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that VAL201 has now entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital ("UCLH") involving patients with hormone-sensitive and hormone-resistant prostate cancer.

This stage of the trial follows approval received from the Medicines and Healthcare products Regulatory Agency ("MHRA") to escalate VAL201 dosing (announced by the Company on18 December 2017).  In the intervening period, the Company has geared up the compound supply chain to meet increased demand for the drug, as a result of the higher dosage to be administered.  UCLH has spent the period both screening and recruiting patients who are eligible to enter this stage of the study.

The current cohort has already received the escalated dose. This marks the point that VAL201 entered the concluding stages of the Phase l/ll clinical trial.  The VAL201 compound has already demonstrated consistent safety and tolerability and signs of activity in previous patients treated with lower dosages.

UCLH continues to recruit suitable patients to complete the trial.  Further results will be announced as they become available and have been verified.

Dr Satu Vainikka, CEO of ValiRx, commented: "I am delighted that this trial is ongoing and reaching the final stages and I look forward to the trial further impacting positively on the lives of current and future patients".

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL